Importantly, the drug gained fast approval from the Chinese National Medical Products Administration (NMPA) for patients with HER 2 OE (score 2+/3+) gastric cancer who had previously received at least two lines of chemotherapy and for pretreated patients with HER2 OE (score 2+/3+) urothelial carcinoma [116,117]. This evidence concerns the gene ERBB2 and gastric cancer.